The UC Davis Cancer Center Biorepository was created in 2004 to provide quality cancer-related human biospecimens that are procured, stored and annotated using international standards of best practices and protocols that are Office for Human Research Protection (OHRP) compliant. The biorepository functions as a centralized tissue bank that provides all cancer center members with an efficient, high quality, stable, reliable, cost-effective access to cancer-related specimens and histology services.
The specific aims of the Biorepository shared resource are: The primary objectives of the CCB shared resource are to facilitate cancer related research at UC Davis by 1 procuring, preparing, storing and dispersing human cancer-related biospecimens from a centralized cancer center biorepository; 2 providing pathological and clinical annotated data using a secure database (caTissue) 3 ensuring compliance with all mandated regulatory processes (HHS, IRB, HIPAA, SRC) thereby promoting ethical research by UC Davis researchers; 4 providing experienced pathologic consultation to investigators 5 efficiently prioritizing, tracking and dispersing biospecimen requests via a rapid, web-based approval and monitoring process 6 providing Tissue Microarray (TMA) construction and histology services for Cancer Center investigators The long-term objective of the CCSR is to facilitate scientific interactions and enhance scientific productivity by providing well-characterized, high-quality cancer-related specimens with annotated data for clinical and basic science research purposes.

Public Health Relevance

The resource provides tissue in various forms of storage as well as bodily fluids that are used in basic cancer research and in animal models of cancer to improve scientific understanding of tumors, tumor development, and anti-tumor therapies with benefit, ultimately, to how cancer patients are treated and cured of disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-11
Application #
8741024
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-07-01
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
11
Fiscal Year
2013
Total Cost
$165,318
Indirect Cost
$57,630
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Zhang, Jin; Lucchesi, Christopher; Chen, Xinbin (2016) A new function for p53 tetramerization domain in cell fate control. Cell Cycle 15:2854-2855
Vinall, Ruth L; Tepper, Clifford G; Ripoll, Alexandra A Z et al. (2016) Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. Genes Cancer 7:86-97
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2016) A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study. Leuk Lymphoma 57:2307-14
Taché, Véronique; Bivina, Liga; White, Sophie et al. (2016) Lipoyltransferase 1 Gene Defect Resulting in Fatal Lactic Acidosis in Two Siblings. Case Rep Obstet Gynecol 2016:6520148
Lara, Joshua; Brunson, Ann; Keegan, Theresa H M et al. (2016) Determinants of Survival for Adolescents and Young Adults with Urothelial Bladder Cancer: Results from the California Cancer Registry. J Urol 196:1378-1382
Faisal, Farzana A; Sundi, Debasish; Tosoian, Jeffrey J et al. (2016) Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. Eur Urol 70:14-7
Dang, Julie H T; Chen Jr, Moon S (2016) Increasing Hepatitis B Testing and Linkage to Care of Foreign-Born Asians, Sacramento, California, 2012-2013. Public Health Rep 131 Suppl 2:119-24
Rowson-Hodel, Ashley R; Berg, Anastasia L; Wald, Jessica H et al. (2016) Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells. Cancer Lett 375:62-72
Zhao, Yong; Tu, Mei-Juan; Wang, Wei-Peng et al. (2016) Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep 6:26611
Monjazeb, Arta M; Kent, Michael S; Grossenbacher, Steven K et al. (2016) Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. Clin Cancer Res 22:4328-40

Showing the most recent 10 out of 608 publications